Presentation
Breast tattoos for planning surgery following neoadjuvant chemotherapy

Presented at the 8th Annual Meeting of the American Society of Breast Surgeons, Phoenix, AZ, May 2–6, 2007
https://doi.org/10.1016/j.amjsurg.2007.07.009Get rights and content

Abstract

Background

Although neoadjuvant chemotherapy is increasingly used for breast cancer, if a patient has a complete clinical response, it is often difficult for the surgeon to know exactly where and how much breast tissue to remove.

Methods

A method is described where the edges of the tumor are tattooed prior to chemotherapy, allowing all tissue initially involved with tumor to be resected following the chemotherapy.

Results

Thirty-four cases have been tattooed prior to neoadjuvant chemotherapy, and the clinical and pathological complete response rates were 56% and 22%, respectively. The tattoos allowed very accurate localization of the residual tumor location and extent. Of the 22 patients who have so far undergone lumpectomy, 77% had residual pathologic evidence of tumor, but the margins were negative in 91% at the first operation. Only 2 patients had to undergo a mastectomy because of persistently positive margins.

Conclusions

The technique of breast tattooing is a simple and practical method to guide the extent of breast surgery following neoadjuvant chemotherapy. In contrast to placement of clips, the technique does not require needle localization, and it allows accurate determination of the initial tumor size and margins.

References (7)

  • B. Fisher et al.

    Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

    J Clin Oncol

    (1998)
  • H.D. Bear et al.

    The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from the National Surgical Adjuvant Breast and Bowel Project Protocol B-27

    J Clin Oncol

    (2003)
  • H.D. Bear et al.

    Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27

    J Clin Oncol

    (2006)
There are more references available in the full text version of this article.

Cited by (21)

  • Preoperative chemotherapy for T2 breast cancer is associated with improved surgical outcome

    2015, European Journal of Surgical Oncology
    Citation Excerpt :

    The advantage of PC prior to surgery is the chance to achieve negative margins while resecting less tissue due to tumor shrinkage. Lannin et al.29 reported the required tissue resection volume to be to 4 times greater than the tumor itself for 3–5 cm tumor. So PC gives the chance to achieve negative margins while resecting smaller volumes even you resect the entire involved breast tissue.

  • The Neoadjuvant Net: A patient- and surgeon-friendly device to facilitate safe breast-conserving surgery in patients who underwent neoadjuvant treatment

    2012, Breast
    Citation Excerpt :

    For this reason, in our Institution we strongly believe that removing all the pre-neoadjuvant tumor burden is mandatory during breast-conserving treatment. Not considering this standard could lead to an unjustified elevated number of positive margins, and IBRTs requiring multiple surgeries.26 Radical BCS can be extremely complex because the necrotic tissue which replaces the tumor cells is always softer and, consequently, less palpable, above all, in cases of a complete clinical response.

  • Breast conservative surgery after neoadjuvant chemotherapy in breast cancer patients: Comparison of two tumor localization methods

    2011, European Journal of Surgical Oncology
    Citation Excerpt :

    If all the volume of the original tumor had to be excised after NAC, it may eliminate the advantage of the preoperative treatment. The main advantage of the preoperative treatment is that negative margins can be achieved without resecting a wide area of normal breast tissue around the tumor.7 The panel of the 2003 consensus conference on NAC in breast cancers recommended marking the tumor site.8

  • Neoadjuvant chemotherapy for operable breast cancer: Individualizing locoregional and systemic therapy

    2010, Surgical Oncology Clinics of North America
    Citation Excerpt :

    In addition, we routinely tattoo the skin overlying the margins of the palpable tumor mass in the breast (usually at the time of venous access placement in the operating room), even if the patient has had a clip placed in the tumor (Fig. 6). This marking is a valuable aid to the ongoing clinical evaluation of the tumor response during therapy and helps to plan surgery, often making wire localization of the tumor site unnecessary.52 Space does not allow a detailed review of the different chemotherapy regimens that can be used in the neoadjuvant setting for operable breast cancers.

  • Breast conservation in locally advanced breast cancer in developing countries: Wise or waste

    2009, Surgical Oncology
    Citation Excerpt :

    Breast conservative surgery in such patients might prove to be difficult unless the primary tumor area had been marked previously. For a patient who is about to receive NACT it is therefore important to mark the exact tumor location by any of the various techniques discussed in the previous few paragraphs under mammographic or sonographic guidance especially in patients with dense breasts [42–47]. This can be performed either at the time of the initial core biopsy or subsequently when there is clinical evidence of response.

View all citing articles on Scopus
View full text